MHRA annual report and accounts 2024 to 2025.
Similar Posts
Class 4 Medicines Defect Notification: Rayner Pharmaceuticals Limited, Dropodex 0.1% w/v Eye Drops, solution, EL(26)A/10
Rayner Pharmaceuticals limited have informed the MHRA that the batches listed in this notification do not include the concentration of phosphates in the product information.
Blood: authorisations and safety reporting
Information about ensuring blood and blood component safety.
Guidance: MORE Submissions – user reference guide
A step-by-step guide on using the MORE Platform for Submissions of device related incidents.
AI Airlock, CERSIs and a new global AI network for health regulators
Med Tech Regs blog, June 2025: A focus on Software and AI.
Class 4 Medicines Defect Notification: Dulcolax Adult 5 mg Gastro-resistant Tablets, Opella Healthcare UK, EL(25)A/26
Opella Healthcare UK LTD has informed the MHRA that there is an error on the artwork for the outer carton of Dulcolax Adult 5mg GR Tablets (packsize 20 count). The dose instruction incorrectly states for use in 12 years and older. These general sale packs are intended for use only in adult patients (18 years and over).
Regulation of AI in Healthcare
The MHRA is seeking evidence on the regulation of AI in healthcare to inform the recommendations of the National Commission into the Regulation of AI in Healthcare.